Edition:
India

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.80EUR
18 Oct 2019
Change (% chg)

€-0.04 (-1.23%)
Prev Close
€2.84
Open
€2.83
Day's High
€2.83
Day's Low
€2.80
Volume
11,155
Avg. Vol
42,115
52-wk High
€3.78
52-wk Low
€2.58

Summary

Name Age Since Current Position

Frederic Grimaud

55 2002 Chairman of the Supervisory Board

Thomas Lingelbach

55 2013 Chairman of the Management Board, Member of the Executive Committee

Franck Grimaud

52 2013 Chief Executive Officer, Member of the Management Board, Member of the Executive Committee

James Sulat

68 2013 Independent Vice Chairman of the Supervisory Board

David Lawrence

55 2017 Chief Financial Officer, Member of the Management Board

Manfred Tiefenbacher

Vice President - Finance, Member of the Executive Committee

Frederic Jacotot

2017 Vice President, General Counsel, Member of the Management Board, Member of the Executive Committee , General Secretary

Jason Golan

Vice President Commercial Operations, Member of the Executive Committee

Olivier Jankowitsch

2017 Vice President Global Supply Operations, Member of the Executive Committee

Andreas Meinke

Vice President Pre-clinical & Translational Research, Member of the Executive Committee

Michael Moehlen

Vice President Corporate Technical Development, Member of the Executive Committee

Klaus Schwamborn

Vice President - Discovery Research & Innovation, Member of the Executive Committee

Wolfgang Bender

65 2017 Chief Medical Officer, Member of the Management Board, Member of the Executive Committee

Frances Muir

CEO Livingstone, Member of the Executive Committee

Anne-Marie Graffin

58 2013 Independent Member of the Supervisory Board

Sandra Poole

55 2017 Independent Member of the Supervisory Board

Louisa Shaw-Marotto

51 2016 Independent Member of the Supervisory Board

Alexander von Gabain

68 2013 Independent Member of the Supervisory Board

Mailys Ferrere

56 2016 Member of the Supervisory Board - Representative of Bpifrance Participation

Balaji Muralidhar

40 2017 Member of the Supervisory Board

Laetitia Bachelot-Fontaine

2012 Head of Investor Relations and Corporate Communications

Biographies

Name Description

Frederic Grimaud

Mr. Frederic Grimaud has been Chairman of the Supervisory Board of VALNEVA SE (Vivalis SA) since November 29, 2002. He was Member of the Audit Committee, Strategy and Transactions Committee, and Nominating and Remuneration Committee. He created a company specializing in services for businesses involved in motivational management of human resources and then joined Groupe Grimaud in 1988 to work in the sales division. In the early 1990’s, he participated in the international development of Groupe Grimaud and led biotechnology projects before becoming Chairman of the Management of Board in 2000. Between 2002 and 2015 he served as Chairman of Grimaud Freres Selection SAS and Hypharm SAS, among others. He is currently Chairman of Filavie SAS and Pen Ar Lan SA as well as Member of the Supervisory Board of Genesis Investment, among others.

Thomas Lingelbach

Mr. Thomas Lingelbach has been Chairman of the Management Board and Member of the Executive Committee of VALNEVA SE since May 10, 2013. He previously served as Chairman of the Management Board and Executive Board, Co-President, Chief Executive Officer of Valneva SE as of 2012. He served at Intercell as of 2006, serving as COO until 2011 and then as its CEO. He joined Intercell from Novartis Vaccine & Diagnostics as Managing Director Germany focusing on the integration with Chiron Vaccine where he served as Vice President Global Industrial Operations and Managing Director Chiron-Behring. Mr. Lingelbach holds a Master's degree in Engineering and complemented his education with a Business Administration program. Currently he is Manager of Gratzelmixer GmbH, Director of Valneva UK and Valneva Canada as well as Chairman of Vaccines Holdings Sweden AB, among others.

Franck Grimaud

Mr. Franck Grimaud has been Chief Executive Officer, Member of the Management Board, Member of the Executive Committee of VALNEVA SE since May 10, 2013. He was Member of the Management Board, Co-President and Chief Business Officer of Valneva SE (Vivalis SA) as of the Company's merger in 2012. Previously he was the Chairman of the Management Board and the Executive Committee of Vivalis SA from November 29, 2002 to 2012. He holds a Master in Business Administration from Ottawa University, and started his career as an organization and management consultant. He then joined Groupe Grimaud as Head of Development for Asia and then became Head of Development of the Veterinary Vaccines Division before creating Vivalis. He was also appointed Vice Chairman of the Atlantic Biotherapies business cluster and his present and former positions include Chief Executive Officer of Smol Therapeutics SAS, President and Representative Director of Vivalis Toyama Japan KK, and Director of Grimaud Deyang Animal Co Ltd and Chengdu Grimaud Breeding Co Ltd.

James Sulat

Mr. James R. Sulat has been Independent Vice-Chairman of the Supervisory Board of VALNEVA SE since March 7, 2013. He is Chairman of company's Audit Committee. He served as CFO for Chiron and CEO of Maxygen. Currently he holds various posts including Board Member at Momenta Pharmaceuricals, AMAG Pharmaceuticals Inc and Arch Therapeutics Inc.

David Lawrence

Mr. David Lawrence has been Chief Financial Officer, Member of the Management Board of VALNEVA since August 1, 2017. He has over 25 years of experience in the pharmaceutical, biotech and vaccine industries, with a proven international track record in mid-sized to large companies and small biotech start-ups. His tested leadership experience as a CFO in the Lifesciences sector spans across finance and accounting, mergers and acquisitions, fund raising and investor relations. He served as CFO in a dual-listed (LSE and NASDAQ) vaccine biotech company (Acambis plc, acquired by sanofi in 2008) and was Vice President of Finance & Business Development for Chiron Vaccines, a division of Chiron Corporation which was acquired by Novartis in 2005. Prior to these roles, he held senior finance positions at GlaxoSmithKline including Vice President of Financial Management in Research and Development. He is currently also Board Member at Valneva Sweden AB, Vaccines Holdings Sweden and Valneva Canada Inc., among others.

Manfred Tiefenbacher

Frederic Jacotot

Mr. Frederic Jacotot has been Vice President, General Counsel, General Secretary, Member of the Executive Committee and Member of the Management Board of VALNEVA SE since April 1, 2017. He is responsible for Legal & Business Compliance, IP. He is currently also Board Member at Valneva Sweden AB and Vaccines Holdings Sweden AB as well as Manager of Valneva Austra GmbH.

Jason Golan

Olivier Jankowitsch

Mr. Olivier Jankowitsch is Vice President Global Supply Operations, Member of the Executive Committeeof VALNEVA SE. He was previously responsible for Corporate Development, Manufacturing and Commercial Alliance projects and served as VP Corporate Development and Member of the Executive Committee.

Andreas Meinke

Michael Moehlen

Klaus Schwamborn

Mr. Klaus Schwamborn is Vice President - Discovery Research & Innovation, Member of the Executive Committee of VALNEVA SE. He is responsible for Discovery Research, new technologies and platforms, open Innovation and Collaboration, EB66 support/services.

Wolfgang Bender

Dr. Wolfgang Bender M.D., Ph.D., is Chief Medical Officer, Member of the Executive Committee and Member of the Management Board of the Company. He is a global life sciences leader with over 30 years of extensive experience in scientific-medical affairs, R&D and general management of vaccines and pharmaceuticals. He has a broad international profile with an exceptional academic background (MD/PhD, MPH, MHA, DTM&P). He has special competencies in strategy, operational execution and change management, with a record of success working in leadership roles for leading global life sciences companies. He held a variety of senior and international positions in vaccine development and medical affairs, working for leading companies in the field, including Novartis Vaccines and Takeda Vaccines. Prior positions included country manager, corporate strategy and various clinical research roles at major pharmaceutical companies such as Pfizer and the Hoechst Group.

Frances Muir

Anne-Marie Graffin

Ms. Anne-Marie Graffin has been Independent Member of the Supervisory Board of VALNEVA SE since March 7, 2013. Ms. Graffin is Member of company's Nominating and Remuneration Committee. She serves as Member of the Supervisory Board at NANOBIOTIX S.A., Non-Executive Independent Director at SARTORIUS STEDIM BIOTECH S.A. and Manager of SARL SMAG Consulting. She holds degree from ESSEC Business School.

Sandra Poole

Ms. Sandra E. Poole has been Independent Member of the Supervisory Board of Valneva SE since June 29, 2017. She is Member of company's Audit Committee. She was Chief Operating Officer of LogicBio Therapeutics Inc. Currently she serves as Managing Director of S. Poole Consulting, LLC.

Louisa Shaw-Marotto

Ms. Louisa Shaw-Marotto has been Independent Member of the Supervisory Board of VALNEVA SE since June 30, 2016. She is Member of company's Audit Committee. She serves as President of Executive Perspective Consulting LLC and Advisory Board Member of Rutgers University and is former Vice President of Marketing at Merck & Co.

Alexander von Gabain

Mr. Alexander von Gabain has been Independent Member of the Supervisory Board of VALNEVA SE since March 7, 2013. He is co-founder and former CEO of INTERCELL. He was also Deputy Vice-Chancellor for Innovation and Commercial Outreach at the Karolinska Institute in Stockholm from 2014 until 2017. Since 2017 he has been Chairman of the Supervisory Board of EIT Health.

Mailys Ferrere

Ms. Mailys Ferrere has been Member of the Supervisory Board - Representative of Bpifrance Participation at Valneva SE since June 30, 2016. She is Member of company's Audit Committee. Currently, Ms. Ferrere serves also as Board Member at SEQUANS Communications SA, DBV Technologies and Euronext Paris. She also represents Bpifrance Participations at Innate Pharma as Member of its Supervisory Board.

Balaji Muralidhar

Dr. Balaji Muralidhar has been Member of the Supervisory Board of VALNEVA SE since June 29, 2017. He is Member of company's Nominating and Remuneration Committee. He is currently Board Member at Zipline Medical Inc., Onbone Oy and Wilson Therapeutics AB.

Laetitia Bachelot-Fontaine